Tests ravulizumab in pregnant people with severe preeclampsia
Tests ravulizumab in pregnant adults with severe preeclampsia and HELLP syndrome.
Plain-language title generated from the registry record
Registry title: Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Key facts
- Where
- Rochester, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT06333652, who can take part
Where in United States
- Mayo Clinic MinnesotaRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT06333652
- Record updated
- 22 October 2026
- Original description
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.Read full original descriptionShow less
Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Inclusion: Individuals with < 34 0/7 weeks of gestation; Individuals with severe preeclampsia or HELLP features.
Exclusion: Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent; Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).